OncoMatch/Clinical Trials/NCT06714383
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Is NCT06714383 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Trilaciclib and Pirarubicin for osteosarcoma.
Treatment: Trilaciclib · Pirarubicin · Lobaplatin — To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Osteosarcoma
Disease stage
Required: Stage Ⅱ, Ⅲ (Enneking)
Grade: high grade
Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06714383 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage Ⅱ or Ⅲ is required.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages